MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
Recurrent Melanoma (Skin) · Metastatic Melanoma · Melanoma Stage IV · Melanoma Stage III
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
2 insiders sold shares within a month
Since Sep 4, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 300 (planned)
- Started
- Jun 1, 2023
- Main results expected
- Dec 31, 2027
- Fully finished
- Dec 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of subjects with dose-limiting toxicities (DLTs) after the first administration of [212Pb]VMT01 as a monotherapy or in combination with nivolumab.
Measured over: Incidence of DLTs during the first 42 days of study Treatment will be assessed.
Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measured over: Up to approximately 2 years
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) following administration of [212Pb]VMT01 as a monotherapy or in combination with nivolumab
Measured over: Up to approximately 2 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.8, since 2026-09-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05655312 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC